期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.699478
关键词
gamma delta T cell; neutrophil; anti-VEGFR2 therapy; breast cancer; IL17A; therapy resistance
类别
资金
- National Natural Science Foundation of China [81930079, 81872317, 81902981, 81902626]
- Health Commission of Zhejiang Province [WKJ-ZJ-1803]
This study demonstrates that low-dose VEGFR2 mAb or VEGFR2-TKI can effectively control the progression of breast cancer, while high-dose treatment is ineffective. High-dose anti-VEGFR2 therapy induces IL17A expression in gamma delta T cells through VEGFR1-PI3K-AKT pathway activation, leading to N2-like neutrophil polarization and CD8(+) T cell exhaustion, creating an immunosuppressive microenvironment. Combining anti-VEGFR2 therapy with immunotherapy targeting the immunomodulatory axis of gamma delta T17 cells-N2 neutrophils shows promising therapeutic effects in breast cancer treatment.
Angiogenesis is an essential physiological process and hallmark of cancer. Currently, antiangiogenic therapy, mostly targeting the vascular endothelial growth factor (VEGF)/VEGFR2 signaling axis, is commonly used in the clinic for solid tumors. However, antiangiogenic therapies for breast cancer patients have produced limited survival benefits since cancer cells rapidly resistant to anti-VEGFR2 therapy. We applied the low-dose and high-dose VEGFR2 mAb or VEGFR2-tyrosine kinase inhibitor (TKI) agents in multiple breast cancer mouse models and found that low-dose VEGFR2 mAb or VEGFR2-TKI achieved good effects in controlling cancer progression, while high-dose treatment was not effective. To further investigate the mechanism involved in regulating the drug resistance, we found that high-dose anti-VEGFR2 treatment elicited IL17A expression in gamma delta T cells via VEGFR1-PI3K-AKT pathway activation and then promoted N2-like neutrophil polarization, thus inducing CD8(+) T cell exhaustion to shape an immunosuppressive microenvironment. Combining anti-VEGFR2 therapy with immunotherapy such as IL17A, PD-1 or Ly-6G mAb therapy, which targeting the immunomodulatory axis of gamma delta T17 cells-N2 neutrophils in vivo, showed promising therapeutic effects in breast cancer treatment. This study illustrates the potential mechanism of antiangiogenic therapy resistance in breast cancer and provides synergy treatment for cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据